Navigation Links
bioTheranostics' CancerTYPE ID® Linked With Improved Clinical Outcome and Longer Survival

SAN DIEGO, Nov. 2, 2011 /PRNewswire/ -- bioTheranostics, Inc., a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, today announced clinical study findings that link CancerTYPE ID® molecular testing with improved patient outcome.  Patients in which CancerTYPE ID predicted a colorectal site of origin that subsequently received site-specific therapy had a median survival three times that of what has been reported in patients treated empirically for cancer of unknown primary (CUP). These results make CancerTYPE ID the only marketed molecular cancer classifier to demonstrate therapeutic response and patient benefit based on molecular tumor profiling.


The study, led by John Hainsworth, MD, of the Sarah Canon Research Institute,  A Retrospective Study of Treatment Outcomes in Patients with Carcinoma of Unknown Primary Site and a Colorectal Cancer Molecular Profile, focused on the improved treatment response and survival in a group of patients in which CancerTYPE ID results were utilized in the selection of site-specific therapy.  According to the study findings, which will be published in the December issue of Clinical Colorectal Cancer and currently are available online, 75 percent of the patients showed negative colonoscopy results, and approximately half the patients had atypical immunohistochemistry for colorectal cancer. Significantly, CancerTYPE ID was used as part of the routine work-up and site-specific treatment was selected based on the molecular assay prediction.  

The study results demonstrated a 50 percent response rate in patients treated with first-line regimens for colorectal cancer versus only 17 percent in patients treated with current empiric therapies for CUP (P value = 0.0257).  Patients predicted to have colorectal cancer by CancerTYPE ID and treated with colorectal cancer treatment regimens experienced a median survival of 27 months. In comparison, patients treated with empiric CUP treatment have historical median survivals ranging from 8 to 11 months.

"The median survival in this select group is substantially better than the historical median survival for CUP patients when treated with empiric CUP regimens," said F. Anthony Greco, MD, Director of the Sarah Cannon Research Institute and senior author of the study.

"Targeted therapies for metastatic cancers require precise knowledge of both tissue origin and underlying disease pathways.  CancerTYPE ID provides critical information on cellular context," said Mark Erlander, PhD, Chief Scientific Officer of bioTheranostics.

CancerTYPE ID is a 92-gene molecular classification test that has been shown to discriminate among tumor types that pose diagnostic dilemmas, including neuroendocrine subtypes often associated with metastasis.  The test classifies 30 main tumor types, 54 subtypes and 106 different morphologies, covering more than 95 percent of all solid tumors.  

"This study demonstrates both diagnostic and therapeutic utility of CancerTYPE ID in metastatic cancer management," said Richard Ding, Chief Executive Officer of bioTheranostics. "We are pleased to provide more evidence that CancerTYPE ID continues to set new standards in the emerging field of molecular cancer classifiers."

About bioTheranostics

Advancing Molecular Diagnostics in Oncology

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: breastcancerindex, which is a prognostic test that provides quantitative risk assessment of distant recurrence in patients diagnosed with estrogen receptor positive and lymph node negative breast cancer; and CancerTYPE ID, which uses the differential expression of 92 genes to aid in the determination of tumor site of origin. For more information, call 1-858-587-5870 or visit

About bioMerieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for more than 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2010, revenues reached euro 1.357 billion with 87% of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at


Tim Schofield
Tel: + 1 858 587 5890

Koren Wolman-Tardy
Tel: + 011 33 6 13 94 51 14

SOURCE bioTheranostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
2. Data From Three Clinical Studies of bioTheranostics Breast Cancer Molecular Test Presented at CTRC-AACR San Antonio Breast Cancer Symposium
3. Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
4. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
5. Crestor and Zocor Drugs Linked to Muscle Degeneration, Rhabdomyolysis
6. Omeros Unlocks Orphan GPCRs Linked to Leukemia and Sleep Disorders
7. Food Allergies Common among Children and Linked to Environmental Allergies and Asthma Later in Life, Suggests Largest-Ever National Allergy Study
8. Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction
9. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
10. GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimers Disease
11. New Study Reveals Proprietary Saw Palmetto Extract (SPET-085) Supplement Can Effectively Inhibit the Enzyme Linked to Benign Prostatic Hyperplasia (BPH)
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... As part ... For Empowerment ™ attracts volunteers together who want to combine talents and resources ... key stakeholders in the process. The non-profit launched its first major fundraiser on ...
(Date:11/25/2015)... ... 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared sauna ... and far-infrared saunas. , For traditional saunas, Finnleo is offering 20% ... wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably grown ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... sauna parts and accessories. , Sauna accessories help improve the bather experience in ... personality. From basic styles for the purist looking for simplicity in design to ...
(Date:11/25/2015)... ... 26, 2015 , ... Ministers, senior government and UN agencies, ... Centres of Excellence, and public R&D institutions, civil societies and other partners gathered ... 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- ...
(Date:11/25/2015)... ... 2015 , ... For the first time, Vitalalert is donating half of its ... The partnership between the two groups began in 2014 with Vitalalert pledging a portion ... International was founded in 1954 and is an international Christian-based health organization whose mission ...
Breaking Medicine News(10 mins):